Brentuximab vedotin

Research use only, not for human use.

Brentuximab vedotin (SGN-35) is a CD30-targeting antibody-active molecule conjugate (ADC) that combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E for the study of lymphoma.

Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.

Cell Cytotoxicity Assay Cell Line:Karpas 299 cells Concentration:1 μg/mL Incubation Time:96 h Result:Showed cytotoxicity to CD30+ Karpas 299 cells with an IC50 value of 2.5 ng/mL.Cell Cycle Analysis Cell Line:L540 cells Concentration:1 μg/mL Incubation Time:12, 24, and 48 h Result:Selectively induced growth arrest in G2/M phase to apoptotic cell death.

Animal Model:SCID miceDosage:10 to 120 mg/kg Administration:Intravenous injection; 10 to 120 mg/kg; for 3 weeks Result:Showed an maximum tolerated dose between 30 and 40 mg/kg.Animal Model:SCID mice Dosage:0.3 and 1 mg/kg Administration:Flanks injection; 1 mg/kg every 4 days for a total of 4 doses; 0.3 mg/kg every 4 days for a total of 4 doses Result:Induced complete and durable tumor regression, but 0.3 mg/kg provided lower therapy than 1 mg/kg dose.

——

Others

Other Targets

Antibody-Drug Conjugates (ADCs)

——

——

914088-09-8

Approximately 145.58 kDa.

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years